PRKCQ Antibody

What are the recommended applications for PRKCQ antibodies in experimental research?

PRKCQ antibodies have been validated for multiple experimental applications, with specific dilution requirements for optimal results:

It is essential to titrate each antibody in your specific experimental system to achieve optimal signal-to-noise ratio. PRKCQ antibodies have demonstrated reliable detection in human cell lines including Jurkat cells, MOLT-4 cells, and K-562 cells .

What is the molecular weight of PRKCQ and how does this affect antibody detection?

PRKCQ has a calculated molecular weight of 82 kDa based on amino acid sequence, but is typically observed at 72-74 kDa in experimental systems . This discrepancy between calculated and observed molecular weights should be considered when interpreting Western blot results. The protein consists of 706 amino acid residues with an amino-terminal regulatory domain (approximately residues 1-378) and a carboxy-terminal catalytic domain (approximately residues 379-706) .

When validating a new PRKCQ antibody, researchers should first confirm band detection at the expected molecular weight in positive control samples (e.g., Jurkat or MOLT-4 cell lysates) before proceeding to experimental samples.

How should PRKCQ antibodies be stored to maintain reactivity?

PRKCQ antibodies require specific storage conditions to maintain functionality:

• Store at -20°C (for most antibodies) or -80°C (for specialized formats)

• Most formulations remain stable for one year after shipment when properly stored

• Some antibodies are supplied in PBS with 0.02% sodium azide and 50% glycerol (pH 7.3)

• Aliquoting is generally unnecessary for -20°C storage, but may be advisable for frequently used antibodies to avoid freeze-thaw cycles

• Some specialized antibody preparations (20μl sizes) contain 0.1% BSA for additional stability

When working with conjugation-ready antibodies (e.g., those without BSA or azide), take particular care to follow storage recommendations to preserve functionality.

How can PRKCQ antibodies be used to investigate T-cell activation mechanisms?

PRKCQ plays critical non-redundant roles in T-cell receptor (TCR) signaling, making it an important target for immunological research:

• Activation pathway analysis: PRKCQ antibodies can be used to study the activation of multiple transcription factors including NF-κB, JUN, NFATC1, and NFATC2 in TCR-CD3/CD28-co-stimulated T-cells .

• Phosphorylation status: Phospho-specific antibodies that recognize PRKCQ phosphorylated at S676 can be used to monitor activation state, as phosphorylation is a key regulatory mechanism .

• Immunoprecipitation studies: Using PRKCQ antibodies for immunoprecipitation allows investigation of interaction partners in signaling complexes, particularly with CARD11, BCL10-MALT1 complex components in NF-κB pathway activation .

• Flow cytometry applications: Intracellular staining protocols with PRKCQ antibodies can assess protein expression in different T-cell subpopulations to study differential expression in T-helper (Th) subsets, especially Th2 and Th17 cells that depend on PRKCQ for development .

Research with Prkcq knockout models has demonstrated that PRKCQ is essential for T-cell activation and proliferation through its role in activating NF-κB, AP-1, and NFAT transcription factors, making comparative studies between wild-type and knockout conditions particularly informative .

What considerations are important when using PRKCQ antibodies to study its role in cancer?

PRKCQ has emerging roles in cancer biology that can be investigated using appropriate antibodies:

• Expression profiling: PRKCQ is increasingly found in solid tumors, particularly gastrointestinal stromal tumors (GIST) and ER-negative breast cancers . Antibodies can help establish expression profiles across tumor types and correlate with clinical outcomes.

• Triple-negative breast cancer (TNBC) studies: A subgroup of TNBC requires PRKCQ for growth and survival . When designing experiments:

  • Compare expression between normal and cancerous tissues

  • Assess correlation with other oncogenic markers

  • Consider paired analysis of primary tumors with metastatic sites

• Methodological approach: In TNBC studies, researchers have demonstrated that PRKCQ promotes oncogenic growth via kinase-activity-dependent stimulation of Erk/MAPK signaling . This can be studied through:

  • Combined immunoprecipitation and Western blot analysis to detect activation of downstream targets

  • Use of phospho-specific antibodies to monitor activation states

  • Correlation with cell proliferation, anoikis resistance, and migration assays

• In vivo tumor models: PRKCQ antibodies can be used in immunohistochemistry of xenograft tumor sections to correlate protein expression with tumor growth characteristics . Knockdown studies have demonstrated that shRNA targeting PRKCQ suppresses tumor formation in mouse xenograft models.

How should researchers address potential cross-reactivity when working with PRKCQ antibodies?

Cross-reactivity is a significant concern when working with protein kinase C family members due to structural similarities:

• Isoform specificity validation: PRKCQ (PKCθ) is one of several PKC isoforms. Confirm antibody specificity using:

  • Positive and negative control cell lines with known expression patterns

  • Recombinant protein standards of multiple PKC isoforms

  • Knockout or knockdown validation where possible

  • Comparison with PKC isoform antibody panels

• Technical validation approaches:

  • For Western blot, run lysates from cells known to express multiple PKC isoforms and confirm single band at the expected molecular weight

  • For immunohistochemistry, include absorption controls with recombinant PRKCQ protein

  • For flow cytometry, compare staining pattern with known PRKCQ distribution in immune cells

• Documentation: When publishing, clearly document all validation steps performed to establish antibody specificity, including catalog numbers, clone designations, and detailed methods.

How can researchers reconcile discrepancies between PRKCQ protein and mRNA expression data?

Researchers frequently encounter disparities between protein and transcript levels when studying PRKCQ:

• Integrated analysis approach:

  • Compare protein levels detected by antibodies with RNA-seq or microarray data

  • Consider post-transcriptional regulation mechanisms

  • Evaluate protein stability and turnover rates in different cell types

• Methodological considerations:

  • For low-expressing samples, enhance sensitivity through phospho-enrichment or targeted mass spectrometry

  • Use multiple antibodies targeting different epitopes to confirm protein expression patterns

  • Validate findings with functional assays that measure PRKCQ activity

• Case example: In thyroid cancer studies, PRKCQ-AS1 (antisense RNA) was found to be significantly downregulated at the transcript level in papillary thyroid carcinoma compared to normal tissues . Researchers should investigate whether corresponding protein changes occur and the potential regulatory relationship between the antisense RNA and protein expression.

What controls are essential when studying PRKCQ phosphorylation states?

Phosphorylation-specific antibodies require rigorous controls:

• Essential controls:

  • Dephosphorylation treatment: Samples treated with phosphatases should show diminished signal

  • Phosphomimetic mutants: Cells expressing S→E mutations can serve as positive controls

  • Phospho-null mutants: S→A mutations can serve as negative controls

  • Kinase inhibitor treatments: Treatment with PKC inhibitors like AEB071 should reduce phospho-signal

• Technical considerations:

  • Phospho-epitopes can be labile; sample preparation should include phosphatase inhibitors

  • Signal may be enhanced by enrichment techniques prior to Western blotting

  • Validation should include correlation with functional readouts of PRKCQ activity

• Context specificity: PRKCQ phosphorylation at T538 and S676 occurs in different contexts and may have distinct functional implications . Experimental design should account for these site-specific differences.

How should researchers interpret PRKCQ expression in different T-cell subsets and cancer models?

Context-dependent expression patterns require careful interpretation:

• T-cell subset analysis:

  • PRKCQ has differential roles in T-helper subsets, being particularly critical for Th2 and Th17 development but less important for Th1 responses

  • Flow cytometry with co-staining for subset markers provides the most reliable data on subset-specific expression

  • Functional validation through knockdown/knockout studies in specific subsets is recommended

• Cancer model considerations:

  • Expression patterns differ between cancer types and even within cancer subtypes

  • In breast cancer, PRKCQ enhances growth-factor-independent growth, anoikis resistance, and migration

  • Comparative analysis between primary tumors, metastatic lesions, and normal tissues provides context for interpretation

• Integration with patient data:

  • Correlation with clinical parameters and outcomes in patient cohorts

  • Analysis of publicly available datasets (e.g., TCGA) to validate findings across larger populations

  • Consideration of PRKCQ expression in the context of tumor microenvironment

How can PRKCQ antibodies be utilized in studying the relationship between metabolism and immune function?

Recent research has revealed connections between PRKCQ and metabolic regulation:

• Fasting and mitochondrial function: Studies have demonstrated that fasting regulates mitochondrial function through lncRNA PRKCQ-AS1 . Researchers can investigate this using:

  • Co-immunoprecipitation of PRKCQ with metabolic regulators

  • Analysis of PRKCQ localization in relation to mitochondria during fasting/feeding cycles

  • Assessment of PRKCQ phosphorylation status in response to metabolic stimuli

• Methodological approach:

  • Combined immunofluorescence and mitochondrial staining to assess co-localization

  • Fractionation studies with PRKCQ antibodies to detect translocation between cellular compartments

  • Correlation of PRKCQ activation with metabolic parameters

• Experimental systems: In vivo models with dietary manipulation (normal diet vs. fasting-mimicking diet) have shown that PRKCQ-AS1 overexpression combined with fasting significantly decreased tumor size . Similar approaches can be used to study PRKCQ protein levels and activation.

What is the optimal approach for studying PRKCQ in the context of potential therapeutic targeting?

As PRKCQ emerges as a potential therapeutic target, antibody-based research can inform drug development:

• Target validation strategies:

  • Use antibodies to confirm expression in target tissues vs. normal tissues

  • Correlate expression with response to existing therapies

  • Evaluate activated (phosphorylated) status in disease contexts

• Pharmacodynamic marker development:

  • Establish assays to monitor on-target effects of PRKCQ inhibitors

  • Develop immunohistochemistry protocols for clinical sample analysis

  • Standardize flow cytometry panels for immune monitoring

• Combination therapy considerations:

  • PRKCQ inhibitors have been developed for autoimmune diseases but may have applications in cancer

  • Antibody-based research can help identify synergistic pathways for combination approaches

  • Investigation of resistance mechanisms through analysis of PRKCQ pathway components

• Predictive biomarker exploration:

  • Identify patient subgroups likely to respond to PRKCQ-targeted therapies

  • Develop antibody-based assays that could translate to companion diagnostics

  • Correlate PRKCQ expression patterns with genomic features of tumors

Since PRKCQ-deficient mice maintain normal immune responses to most bacterial and viral pathogens but show defects in Th17 development, therapeutic targeting may achieve selective immunomodulation without compromising host defense mechanisms .

What approaches can resolve inconsistent results when using PRKCQ antibodies in different experimental systems?

Researchers frequently encounter variability in antibody performance across systems:

• Cell type considerations:

  • PRKCQ expression varies significantly between cell types; calibrate expectations accordingly

  • For low-expressing samples, use positive controls (e.g., Jurkat cells) alongside experimental samples

  • Consider cell activation state, as PRKCQ levels and localization change upon stimulation

• Technical optimization:

  • For Western blotting: Test multiple lysis buffers as extraction efficiency varies

  • For flow cytometry: Optimize fixation and permeabilization protocols specifically for PRKCQ

  • For immunohistochemistry: Compare antigen retrieval methods as epitope accessibility can be method-dependent

• Antibody selection strategy:

  • When possible, use antibodies validated for your specific application

  • Consider using multiple antibodies targeting different epitopes

  • For phospho-specific detection, ensure samples are properly preserved with phosphatase inhibitors

• Validation approaches:

  • Genetic validation using CRISPR knockout or siRNA knockdown provides the strongest controls

  • Recombinant protein standards can calibrate sensitivity and specificity

  • Peptide competition assays can confirm binding specificity

How should researchers address the challenge of detecting PRKCQ in tissues with low expression levels?

Detection of low-abundance proteins requires specialized approaches:

• Signal amplification methods:

  • For Western blot: Consider using high-sensitivity chemiluminescent substrates or fluorescent detection

  • For IHC/IF: Employ tyramide signal amplification or other amplification systems

  • For flow cytometry: Use bright fluorochromes and optimize voltage settings

• Enrichment strategies:

  • Immunoprecipitate PRKCQ before Western blotting to concentrate the protein

  • For cancer studies, use microdissection to isolate tumor regions with higher expression

  • Consider phospho-enrichment for studying activated forms

• Alternative detection platforms:

  • Proximity ligation assay for in situ detection with improved sensitivity

  • Mass spectrometry-based approaches for unbiased detection

  • Digital ELISA platforms with single-molecule sensitivity

• Contextual examination:

  • Evaluate PRKCQ in contexts known to induce expression (e.g., activated T cells)

  • Consider examining downstream signaling events as indirect evidence of PRKCQ activity

  • Use genetic overexpression systems to validate antibody performance before attempting detection of endogenous protein